Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this ...

After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...

LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...

As far as competition goes, Eli Lilly is one of the two current leaders in the weight loss space, along with Novo Nordisk.

Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

We recently compiled a list of the Jim Cramer on Nvidia Plus Other Stocks. In this article, we are going to take a look at ...

We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to ...

Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.

Eli Lilly And Co (NYSE:LLY) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...